Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 1
2018 2
2019 3
2020 1
2021 4
2022 4
2023 4
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Results by year

Filters applied: . Clear all
Page 1
PGE2 limits effector expansion of tumour-infiltrating stem-like CD8+ T cells.
Lacher SB, Dörr J, de Almeida GP, Hönninger J, Bayerl F, Hirschberger A, Pedde AM, Meiser P, Ramsauer L, Rudolph TJ, Spranger N, Morotti M, Grimm AJ, Jarosch S, Oner A, Gregor L, Lesch S, Michaelides S, Fertig L, Briukhovetska D, Majed L, Stock S, Busch DH, Buchholz VR, Knolle PA, Zehn D, Dangaj Laniti D, Kobold S, Böttcher JP. Lacher SB, et al. Among authors: stock s. Nature. 2024 Apr 24. doi: 10.1038/s41586-024-07254-x. Online ahead of print. Nature. 2024. PMID: 38658748
Comparative performance of scFv-based anti-BCMA CAR formats for improved T cell therapy in multiple myeloma.
Stock S, Fertig L, Gottschlich A, Dörr J, Märkl F, Majed L, Menkhoff VD, Grünmeier R, Rejeski K, Cordas Dos Santos DM, Theurich S, von Bergwelt-Baildon M, Endres S, Subklewe M, Kobold S. Stock S, et al. Cancer Immunol Immunother. 2024 Apr 17;73(6):100. doi: 10.1007/s00262-024-03688-4. Cancer Immunol Immunother. 2024. PMID: 38630291 Free PMC article.
Mutation-specific CAR T cells as precision therapy for IGLV3-21R110 expressing high-risk chronic lymphocytic leukemia.
Märkl F, Schultheiß C, Ali M, Chen SS, Zintchenko M, Egli L, Mietz J, Chijioke O, Paschold L, Spajic S, Holtermann A, Dörr J, Stock S, Zingg A, Läubli H, Piseddu I, Anz D, Minden MD, Zhang T, Nerreter T, Hudecek M, Minguet S, Chiorazzi N, Kobold S, Binder M. Märkl F, et al. Among authors: stock s. Nat Commun. 2024 Feb 2;15(1):993. doi: 10.1038/s41467-024-45378-w. Nat Commun. 2024. PMID: 38307904 Free PMC article.
Severe hematotoxicity after CD19 CAR-T therapy is associated with suppressive immune dysregulation and limited CAR-T expansion.
Rejeski K, Perez A, Iacoboni G, Blumenberg V, Bücklein VL, Völkl S, Penack O, Albanyan O, Stock S, Müller F, Karschnia P, Petrera A, Reid K, Faramand R, Davila ML, Modi K, Dean EA, Bachmeier C, von Bergwelt-Baildon M, Locke FL, Bethge W, Bullinger L, Mackensen A, Barba P, Jain MD, Subklewe M. Rejeski K, et al. Among authors: stock s. Sci Adv. 2023 Sep 22;9(38):eadg3919. doi: 10.1126/sciadv.adg3919. Epub 2023 Sep 22. Sci Adv. 2023. PMID: 37738350 Free PMC article.
Bispecific antibodies redirect synthetic agonistic receptor modified T cells against melanoma.
Märkl F, Benmebarek MR, Keyl J, Cadilha BL, Geiger M, Karches C, Obeck H, Schwerdtfeger M, Michaelides S, Briukhovetska D, Stock S, Jobst J, Müller PJ, Majed L, Seifert M, Klüver AK, Lorenzini T, Grünmeier R, Thomas M, Gottschlich A, Klaus R, Marr C, von Bergwelt-Baildon M, Rothenfusser S, Levesque MP, Heppt MV, Endres S, Klein C, Kobold S. Märkl F, et al. Among authors: stock s. J Immunother Cancer. 2023 May;11(5):e006436. doi: 10.1136/jitc-2022-006436. J Immunother Cancer. 2023. PMID: 37208128 Free PMC article.
Single-cell transcriptomic atlas-guided development of CAR-T cells for the treatment of acute myeloid leukemia.
Gottschlich A, Thomas M, Grünmeier R, Lesch S, Rohrbacher L, Igl V, Briukhovetska D, Benmebarek MR, Vick B, Dede S, Müller K, Xu T, Dhoqina D, Märkl F, Robinson S, Sendelhofert A, Schulz H, Umut Ö, Kavaka V, Tsiverioti CA, Carlini E, Nandi S, Strzalkowski T, Lorenzini T, Stock S, Müller PJ, Dörr J, Seifert M, Cadilha BL, Brabenec R, Röder N, Rataj F, Nüesch M, Modemann F, Wellbrock J, Fiedler W, Kellner C, Beltrán E, Herold T, Paquet D, Jeremias I, von Baumgarten L, Endres S, Subklewe M, Marr C, Kobold S. Gottschlich A, et al. Among authors: stock s. Nat Biotechnol. 2023 Nov;41(11):1618-1632. doi: 10.1038/s41587-023-01684-0. Epub 2023 Mar 13. Nat Biotechnol. 2023. PMID: 36914885 Free PMC article.
Impact of the selective A2AR and A2BR dual antagonist AB928/etrumadenant on CAR T cell function.
Seifert M, Benmebarek MR, Briukhovetska D, Märkl F, Dörr J, Cadilha BL, Jobst J, Stock S, Andreu-Sanz D, Lorenzini T, Grünmeier R, Oner A, Obeck H, Majed L, Dhoqina D, Feinendegen M, Gottschlich A, Zhang J, Schindler U, Endres S, Kobold S. Seifert M, et al. Among authors: stock s. Br J Cancer. 2022 Dec;127(12):2175-2185. doi: 10.1038/s41416-022-02013-z. Epub 2022 Oct 20. Br J Cancer. 2022. PMID: 36266575 Free PMC article.
Chimeric antigen receptor T cells engineered to recognize the P329G-mutated Fc part of effector-silenced tumor antigen-targeting human IgG1 antibodies enable modular targeting of solid tumors.
Stock S, Benmebarek MR, Kluever AK, Darowski D, Jost C, Stubenrauch KG, Benz J, Freimoser-Grundschober A, Moessner E, Umana P, Subklewe M, Endres S, Klein C, Kobold S. Stock S, et al. J Immunother Cancer. 2022 Jul;10(7):e005054. doi: 10.1136/jitc-2022-005054. J Immunother Cancer. 2022. PMID: 35902133 Free PMC article.
20 results